June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Profiles of wAMD patients associated with the number of intravitreal injection: a pooled analysis from the real-world LUMIERE &TWIN retrospective studies
Author Affiliations & Notes
  • Jean-Francois GIRMENS
    CIC1423, CHNO des Quinze-Vingts, Paris, France
  • Franck Fajnkuchen
    Centre d'Imagerie et Laser, Paris, France
  • Eric H Souied
    Ophthalmology, Centre Hospitalier Intercommunal, Créteil, France
  • Joel Uzzan
    Ophthalmology, Clinique Mathilde, Rouen, France
  • Gérard Mimoun
    Centre ophtalmologique de l’école militaire, Paris, France
    Clinique St-Charles, Lyon, France
  • Audrey Derveloy
    Novartis Pharma SAS, Rueil-Malmaison, France
  • Hassiba Oubraham
    Ophthalmology, Private Office, Montargis, France
  • Christian Delhay
    Centre d'ophtalmologie du Mené-Ténénio, Vannes, France
  • Salomon Y Cohen
    Centre d'Imagerie et Laser, Paris, France
  • Footnotes
    Commercial Relationships Jean-Francois GIRMENS, Allergan (C), Bayer (C), Novartis (C), Sanofi-Fovea (C); Franck Fajnkuchen, Allergan (C), Bayer (C), Novartis (C); Eric Souied, Allergan (C), Bayer (C), Novartis (C), Thea (C); Joel Uzzan, Allergan (C), Bayer (C), Novartis (C); Gérard Mimoun, None; Violaine COLASSE-MARTHELOT, Bayer (C), Novartis (C); Audrey Derveloy, Novartis Pharma SAS (E); Hassiba Oubraham, Allergan (C), Bayer (C), Novartis (C); Christian Delhay, Allergan (C), Bayer (C), Novartis (C); Salomon Cohen, Alcon (C), Allergan (C), Bayer (C), Novartis (C), Thea (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1416. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jean-Francois GIRMENS, Franck Fajnkuchen, Eric H Souied, Joel Uzzan, Gérard Mimoun, Violaine COLASSE-MARTHELOT, Audrey Derveloy, Hassiba Oubraham, Christian Delhay, Salomon Y Cohen; Profiles of wAMD patients associated with the number of intravitreal injection: a pooled analysis from the real-world LUMIERE &TWIN retrospective studies. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1416.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Although the mean number of intravitreal treatments (IVTs) was reported to be about 5-6 per year, the distribution pattern of the number of IVTs in patients with neovascular age-related macular degeneration (nAMD) in the real-world setting remains to be defined. In line with this, the baseline predictive factors remain unidentified to determine this number required for a patient. This pooled retrospective analysis from the LUMIERE and TWIN studies aims at describing the distribution pattern of number of IVTs and the characteristics of these patients.

Methods: LUMIERE (N=551) and TWIN (N=881) were similar designed multicenter 12-month retrospective observational studies to evaluate the functional and morphological outcomes in the clinical settings of patients with nAMD treated with ranibizumab (RBZ). Patients were pooled and divided into 3 groups as per the number of IVTs: <5, 5-6, and ≥7. The baseline characteristics and the response to RBZ with respect to change in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy [ETDRS] letters) from baseline to Month 12 were analyzed.

Results: 39.6%, 31.8%, and 28.6% of patients received <5, 5-6, and ≥7 IVTs, respectively. Overall, the majority (65.9%) was females; mean age (78.9 years) was similar across all the 3 groups. The mean baseline BCVA was significantly lower in the <5 IVT group compared to the other 2 groups (<5IVTs: 53.4 ± 20.2, 5-6IVTs: 56.5 ± 17.8, and ≥7 IVTs: 57.4 ± 16.8 (p<0.001)). A global difference seems to be present at baseline in each group regarding the types of choroidal neovascularization without the possibility in this posthoc analysis to identify it separately. Over 32% of the patients in ≥7 IVT group had vascularized pigment epithelial detachment (versus <5IVTs: 20%, 5-6IVTs: 25%, p<0.001). At Month 12, the mean change in BCVA ± SD compared with baseline was comparable across the 3 groups (<5IVTs: 5.3 ± 15.2, 5-6IVTs: 3.5 ± 15.3, and ≥7 IVTs: 4.2 ± 14.7 (p=0.773)).

Conclusions: This pooled analysis from the LUMIERE and TWIN studies in nAMD showed that only about one-third of patients received 5-6 IVT. This indicates that the mean number of IVT per year correlates with a minority of patients (32%).<br /> Real life analysis revealed a broad distribution pattern of the number of injections, supporting individualized dosing.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.